QGEN Stock Analysis: Qiagen | NYSE

Molecular Diagnostics, Sample Preparation, PCR Instruments, Sequencing Reagents

Total Rating 48

Safety 85

Buy Signal -0.57

Diagnostics & Research
Industry Rotation: +7.8

Market Cap: 9.27B
Avg Turnover: 122M

Risk 3d forecast

Volatility44.8%

VaR 5^th Pctl7.31%

VaR vs Median-0.84%

Reward TTM

Sharpe Ratio-0.12

Rel. Str. IBD41.6

Rel. Str. Peer Group5.4

Character TTM

Beta0.322

Beta Downside0.264

Hurst Exponent0.610

Drawdowns 3y

Max DD41.38%

CAGR/Max DD0.06

CAGR/Mean DD0.23

EPS (Earnings per Share)

EPS CAGR: 3.59%
EPS Trend: 82.7%

Last SUE: 1.00
Qual. Beats: 1

Revenue

Rev. CAGR: 3.36%
Rev. Trend: 93.9%

Last SUE: 1.15
Qual. Beats: 1

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +1.5% 18

Feb -3.5% 23

Mar +0.4% 5

Apr -1.6% 21

May +2.2% 44

Jun +0.8% 8

Jul +4.5% 46

Aug -1.8% 15

Sep -3.0% 53

Oct -5.3% 13

Nov +1.2% 2

Dec +0.6% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: QGEN Qiagen

Qiagen N.V. (NYSE: QGEN) is a Netherlands-based life sciences company that provides sample-to-insight solutions, converting biological materials into molecular insights for customers worldwide. Founded in 1984 and headquartered in Venlo, the Netherlands, Qiagen is classified within the Life Sciences Tools & Services sub-industry of the Health Care sector.

The companys business model centers on three integrated layers: consumables (kits, reagents, and enzymes used in sample preparation and analysis), instruments (PCR, digital PCR, NGS, and automated sample processing platforms), and bioinformatics/software solutions, including software-as-a-service offerings. This sample to insight approach is designed to give customers a workflow that spans from raw sample collection through data interpretation.

Qiagen serves two primary end markets. In molecular diagnostics, it offers tests for tuberculosis, post-transplant monitoring, sexually transmitted infections, HPV, and prenatal screening. In life sciences research, its products support gene expression analysis, genotyping, human ID/forensics, next-generation sequencing library preparation, and DNA methylation studies. The combination of recurring consumables revenue with instrument placements is a common structural feature of tools and services companies in this sector, supporting ongoing customer relationships beyond initial equipment sales.

Headlines to Watch Out For

Core consumables sales accelerate as post-COVID demand recovers
QIAstat-Dx respiratory panel placements drive instrument revenue growth
Operating margin expansion initiative targets adjusted EBITDA margin lift

Piotroski VR-10 (Strict) 6.5

Net Income: 409.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.92 > 1.0
NWC/Revenue: 51.19% < 20% (prev 33.86%; Δ 17.33% < -1%)
CFO/TA 0.11 > 3% & CFO 654.5m > Net Income 409.3m
Net Debt (1.01b) to EBITDA (785.4m): 1.28 < 3
Current Ratio: 2.85 > 1.5 & < 3
Outstanding Shares: last quarter (207.8m) vs 12m ago -4.75% < -2%
Gross Margin: 61.82% > 18% (prev 62.97%; Δ -1.14% > 0.5%)
Asset Turnover: 35.86% > 50% (prev 35.03%; Δ 0.83% > 0%)
Interest Coverage Ratio: 12.68 > 6 (EBIT TTM 499.9m / Interest Expense TTM 39.4m)

Altman Z'' 4.72

A: 0.18 (Total Current Assets 1.66b - Total Current Liabilities 581.4m) / Total Assets 5.89b
B: 0.48 (Retained Earnings 2.81b / Total Assets 5.89b)
C: 0.09 (EBIT TTM 499.9m / Avg Total Assets 5.86b)
D: 1.33 (Book Value of Equity 3.36b / Total Liabilities 2.53b)
Altman-Z'' = 4.72 = AA

Beneish M -2.96

DSRI: 1.00 (Receivables 399.1m/385.8m, Revenue 2.10b/2.04b)
GMI: 1.02 (GM 62.97% / 61.82%)
AQI: 1.05 (AQ_t 0.56 / AQ_t-1 0.54)
SGI: 1.03 (Revenue 2.10b / 2.04b)
TATA: -0.04 (NI 409.3m - CFO 654.5m) / TA 5.89b)
Beneish M = -2.96 (Cap -4..+1) = A

What is the price of QGEN shares?

As of August 26, 2026, the stock is trading at USD 41.78 with a total of 8,619,758 shares traded. Over the past week, the price has changed by -1.92%, over one month by +0.99%, over three months by +24.86% and over the past year by -4.38%.

Current recommended Stop Loss: 39.50 (which is 5.5% or 1.9 ATR below the current price).

Is QGEN a buy, sell or hold?

Qiagen has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy QGEN.

StrongBuy: 6
Buy: 3
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the QGEN price?

Analysts Target Price	46.1	10.3%

Qiagen (QGEN) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 9.27b (9.27b USD * 1.0 USD.USD)
P/E Trailing = 22.6768
P/E Forward = 13.986
P/S = 4.4143
P/B = 2.7367
P/EG = 1.1195
Revenue TTM = 2.10b USD
EBIT TTM = 499.9m USD
EBITDA TTM = 785.4m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 1.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 157.9m
Net Debt = 1.01b USD (calculated: Debt 1.80b - CCE 793.5m)
Enterprise Value = 10.3b USD (9.27b + Debt 1.80b - CCE 793.5m)
Interest Coverage Ratio = 12.68 (Ebit TTM 499.9m / Interest Expense TTM 39.4m)
EV/FCF = 22.96x (Enterprise Value 10.3b / FCF TTM 447.7m)
FCF Yield = 4.36% (FCF TTM 447.7m / Enterprise Value 10.3b)
FCF Margin = 21.32% (FCF TTM 447.7m / Revenue TTM 2.10b)
Net Margin = 19.49% (Net Income TTM 409.3m / Revenue TTM 2.10b)
Gross Margin = 61.82% ((Revenue TTM 2.10b - Cost of Revenue TTM 801.8m) / Revenue TTM)
Gross Margin QoQ = 63.62% (prev 62.89%)
Tobins Q-Ratio = 1.75 (Enterprise Value 10.3b / Total Assets 5.89b)
Interest Expense / Debt = 2.19% (Interest Expense 39.4m / Debt 1.80b)
Taxrate = 11.37% (52.5m / 461.8m)
NOPAT = 443.1m (EBIT 499.9m * (1 - 11.37%))
Current Ratio = 2.85 (Total Current Assets 1.66b / Total Current Liabilities 581.4m)
Debt / Equity = 0.54 (Debt 1.80b / totalStockholderEquity, last quarter 3.36b)
Debt / EBITDA = 1.28 (Net Debt 1.01b / EBITDA 785.4m)
Debt / FCF = 2.25 (Net Debt 1.01b / FCF TTM 447.7m)
Total Stockholder Equity = 3.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 409.3m / Total Assets 5.89b)
RoE = 11.60% (Net Income TTM 409.3m / Total Stockholder Equity 3.53b)
RoCE = 9.70% (EBIT 499.9m / Capital Employed (Equity 3.53b + L.T.Debt 1.63b))
RoIC = 8.49% (NOPAT 443.1m / Invested Capital 5.22b)
WACC = 6.27% (E(9.27b)/V(11.1b) * Re(7.11%) + D(1.80b)/V(11.1b) * Rd(2.19%) * (1-Tc(0.11)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.47 | Cagr: -3.77%
[DCF] Terminal Value 73.99% ; FCFF base≈467.1m ; Y1≈430.5m ; Y5≈384.0m
[DCF] Fair Price = 24.61 (EV 6.09b - Net Debt 1.01b = Equity 5.08b / Shares 206.5m; r=8.35% [WACC [floored]]; 5y FCF grow -9.80% → 2.50% )
EPS Correlation: 82.71 | EPS CAGR: 3.59% | SUE: 1.00 | # QB: 1
Revenue Correlation: 93.93 | Revenue CAGR: 3.36% | SUE: 1.15 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.62 | Chg30d=-2.18% | Revisions=-62% | Analysts=8
EPS current Year (2026-12-31): EPS=2.43 | Chg30d=-0.31% | Revisions=-17% | GrowthEPS=+2.3% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=2.61 | Chg30d=-0.93% | Revisions=-36% | GrowthEPS=+7.2% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -53% (up=3, down=13)